Quantitation of polymorphic epithelial mucin: a challenge for biochemists and immunologists

References

• Taylor-Papadimitriou J, Peterson J, Arklie J, Burchell J, Ceriani R L, Bodmer W F. Monoclonal antibodies to epithelium specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 1981; 28: 17–21
   PubMed Web of Science ®Google Scholar
• Burchell J, Durbin H, Taylor-Papadimitriou J. Complexety of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2 in normal and malignant human mammary epithelial cells. J Immunol 1983; 131: 508–13
   PubMed Web of Science ®Google Scholar
• Ceriani R L, Peterson J A, Lee J Y, Moncada R, Blank E W. Characterisation of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule. Som Cell Genet 1983; 9: 415–27
   PubMedGoogle Scholar
• Hikens J, Buijs F, Hilgers J, Hageman P H, Calafat J, Sonnenberg A, van der Valk M. Monoclonal antibodies against human milkfat globuline membranes detecting differentiation antigens of the mammary gland and its turnours. Int J Cancer 1984; 34: 197–206
   PubMedGoogle Scholar
• Hilgers J, Zotter S, Kenemans P. Polymorphic epithelial mucin and CA 125-bearing glycoprotein in basic and applied carcinoma research. Cancer Rev11— 1988; 12: 3–10
   Google Scholar
• Zotter S, Philomena C, Hageman Amdt Lossnitzer, Wolter J, Mooi Hilgers J. Tissue and tumour distribution of human polymorphic epithelial mucin. Cancer Rev11/ 1988; 12: 55–101
   Google Scholar
• Gendler S J, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. Highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988; 263: 12820–3
   PubMed Web of Science ®Google Scholar
• Gendler S J, Burchell J M, Duhig T, Lamport D, White R, Parker M, Taylor-Papadimitriou J. Cloning of partial cDNA encoding differentiation and tumour-associated mucin glycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci USA 1987; 84: 6060–4
   PubMed Web of Science ®Google Scholar
• Swallow D M, Gentler S, Griffiths B, Carney G, Taylor-Papadimitriou J, Bramwell M E. The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature (London) 1987; 328: 82
   PubMed Web of Science ®Google Scholar
• Swallow D M, Gentler S, Griffiths B, Keamey A, Povey S, Sheer D, Taylor-Papadimitriou J. The hypervariable gene locus PUM, which codes for the tumourassociated epithelial mucins, is located on chromosome 1, within the region 1q21—24. Ann Hum Genet 1987; 51: 289
   PubMed Web of Science ®Google Scholar
• Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D. Isolation and sequencing of a cDNA coding for the human breast carcinoma-associated antigen. Roc Natl Acad Sci USA 1988; 85: 2320–3
   PubMed Web of Science ®Google Scholar
• Ligtenberg MJL, Vos H L, Gennissen AMC, Hilkens J. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 1990; 265: 5573–8
   PubMed Web of Science ®Google Scholar
• Fontenot J D, Tjandra N, Bu D, Ho C, Montelaro R C, Finn O J. Biophysical characterization of one-, and three-tandem repeats of human mucin (MUC-1) protein core. Cancer Res 1993; 53: 5386–94
   PubMed Web of Science ®Google Scholar
• Gendler S, Lancaster C, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumour-associated polymorphic epithelial mucin. J Biol Chem 1990; 265: 15286–93
   PubMed Web of Science ®Google Scholar
• Hilkens J, Ligtenberg MJL, Vos H L, Litvinov S V. Cell membrane-associated mucins and their adhesion-modulating property. Trends in Biochemical Sciences 1992; 17: 359–63
   PubMed Web of Science ®Google Scholar
• Ligtenberg MJL, Buijs F, Vos H L, Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res 1992; 52: 2318–24
   PubMed Web of Science ®Google Scholar
• Van de Wiel - van Kemenade E, Ligtenberg MJL, de Boer A J, Buijs F, Vos H L, Melief CJM, Hilkens J, Figdor C G. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J of Immunol 1993; 151: 767–76
   PubMedGoogle Scholar
• Behrens J, Mareel M M, VanRoy F M, Birchmeier W. Dissecting tumour cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J of Cell Biol 1989; 108: 2435–47
   PubMed Web of Science ®Google Scholar
• Hilkens J, Kroezen V, Bonfrer J M, De JBM, Bruning P F. MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res 1986; 46: 2582–7
   PubMed Web of Science ®Google Scholar
• Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. a core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989; 43: 1072–6
   PubMed Web of Science ®Google Scholar
• Burchell J, Taylor-Papadimitriou J, Boshell M, Gendler S, Duhig T. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int J Cancer 1989; 44: 691–6
   PubMed Web of Science ®Google Scholar
• Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, Lamport D. Development and characterization of breastcancer reactive monoclonal antibodies directed to the core protein of the human milk rnucin. Cancer Res 1987; 47: 5476–82
   PubMed Web of Science ®Google Scholar
• Devine P L, Warren J A, Ward B G. McKenzie IFC, Layton GT. Glycosylation and the exposure of tumour-associated epitopes on mucins. J Tumour Marker Oncol 1990; 5: 11–26
   Google Scholar
• Burchell J, Wang D, Taylor-Papadimitriou J. Detection of the tumour-associated antigens recognized by the monoclonal antibodies HMFG-1 and 2 in serum from patients with breast cancer. Int J Cancer 1984; 34: 763–8
   PubMed Web of Science ®Google Scholar
• Tobias R, Rothwell C, Wagner J, Green A, Liu Y S. Development and evaluation of a radio-immunoassay for the detection of a monoclonal antibody defined breast tumour associated antigen 115D8/DF3. Clin Chem 1985; 31: 986
   Web of Science ®Google Scholar
• Kufe D, Inghirami G, Abe M, Hayes D, Just-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast turnours. Hybridoma 1984; 3: 223–31
   PubMed Web of Science ®Google Scholar
• Hayes D F, Sekine H, Ohno T, Abe M, Keefe K, Kufe D W. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 1985; 75: 1671–8
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bast RC, Jr, Yedema C A, Price M R, Hilgers J. CA 125 and polymorphic epithelial mucin as serum tumour markers. Cancer Rev11— 1988; 12: 119–44
   Google Scholar
• Bon G G, Kenemans P, van Kamp G J, Yedema C A, Hilgers J. Review on the clinical value of polymorphic epithelial mucin tumour markers for the management of carcinoma patients. J Nucl Med Allied Sci 1990; 34: 151–62
   PubMedGoogle Scholar
• Bieglmayer C, Szepesi T, Neunteufel W, Nowontny C. MCA, a monoclonal-antibody-defined breast-tumour-associated antigen and its relation to CA15.3. Tumour Biol 1989; 10: 232–42
   PubMedGoogle Scholar
• Beveridge R A, Chan D W, Bruzek D, et al. A new biomarker in monitoring breast cancer: CA-549. J Tumour Marker Onc 1989; 6: 1815–21
   Google Scholar
• Konrath J G, Manderino G L, Przywara L W, Elliott R L. IMxTMBCM, an automated microparticle enzyme immunoassay for breast cancer mucin. Clin Chem 1989; 35: 1078
   Google Scholar
• Linsley P S, Brown J P, Magnani J L, Horn D. Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients. Cancer Res 1988; 48: 2138–48
   PubMedGoogle Scholar
• Linsley P S, Ochs V, Laska S, Horn D, Ring D B, Frankel A E, Brown J P. Elevated levels of a high molecular weight antigen detected by antibody sera from breast cancer patients. Cancer Res 1986; 46: 5444–50
   PubMedGoogle Scholar
• Layton G T, King P-X, McKenzie IFC, Bishop J F, McGuckin M A. Cancer associated serum antigen (CASA) and ovarian serum antigen (OSA): two new tumour marker kits for detecting carcinoma-associated mucins. J Tumour Marker Oncol 1991; 6: 9–17
   Google Scholar
• Yedema C A, Kenemans P, Wobbes T, van Kamp G J, de Bruijn H W, Thomas C M, Massuger L F, Schijf C P, Bon G G, Vermorken J B, Voorhorst F, Hilgers J. Carcinoma-associated mucin SeNm markers Ca M26 and CA M29: Efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix. Int J Cancer 1991; 47: 170–9
   PubMedGoogle Scholar
• Verstraeten A A, Bon G G, Kenemans P, van Kamp G J, Hilgers J. Diagnostic and prognostic significance of the mucin serum tumour marker CA M26 and CA M29: Theoretical considerations based on a review of the literature. Updating on tumour markers in tissue and biological fluids: Basic aspects and clinical applications, A Ballesta, G C Torre, E Bombardieri, M Gion, R Molina. Publ Edizione Minerva Medica, TorinoItaly 1993; 575–87
   Google Scholar
• Stenman U H, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α-1-antichrymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222–6
   PubMed Web of Science ®Google Scholar
• Wood W G, Sloot vander E, Bohle A. The establishment and evaluation of luminescent-labelled immunometric assays for prostate-specific antigen α-1-antichrymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 1991; 29: 787–94
   PubMedGoogle Scholar
• Jerome K R, Barnd D L, Bendt K M, Boyer C M, Taylor-Papadimitriou J, McKenzie IFC, Bast R C, Finn O J. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51: 2908–16
   PubMed Web of Science ®Google Scholar
• Hinoda Y, Nakawgawa N, Nakamura H, Makiguchi Y, Itoh F, Adachi M, Yabana T, Imai K, Yachi A. Detection of a circulating antibody against a pepride epitope on a mucin core proein, MUC1, in ulcerative colitis. Immunol Letters 1993; 35: 163–8
   PubMedGoogle Scholar
• Rughetti A, Turchi V, Ghetti C A, Scambia G, Benedetti Panici P, Roncucci G, Mancuso S, Fratti L, Nuti M. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 1993; 53: 2457–9
   PubMedGoogle Scholar
• Nuti M, Rughetti A, Turchi V, Apollonj-Ghetti C, Scambia G, Frati L. Human B cell immun response to selectes epitopes of the polymorphic epithelial mucin (PEM) in cancer patients. In Vivo 1993; 7: 645–8
   PubMedGoogle Scholar
• Gourevitch M M, von Mensdorff-Pouilly S, Litvinov S V, Kenemans P, van Kamp G J, Verstraeten A A, Hilgers J. Polymorphic epithelial mucin (MUC-1) -containing circulating immune complexes in carcinoma patients, Submitted
   Google Scholar
• von Mensdorff-Pouilly S, Gourevitch M M, Kenemans P, Verstraeten A A, Litvinov S V, van Kamp G J, Meyer S, Vermorken J, Hilgers J. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast turnouts, Submitted
   Google Scholar
• Finn O J. Tumour-rejection antigens recognized by T lymphocytes. Current Opinion in Immunol 1993; 5: 701–8
   PubMedGoogle Scholar
• Apostolopoulos V, Pei-Xiang Xing, McKenzie IFC. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens. Cancer Res 1994; 54: 5186–93
   PubMed Web of Science ®Google Scholar
• Acres R B, Hareveuni M, Balloul J M, Kieny M-P. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumours bearing the MUC1 antigen. J Immunother 1993; 14: 136–46
   Web of Science ®Google Scholar
• Pardoll D M. Cancer vaccines. Immunol Today 1993; 14(no 6)310–6
   PubMedGoogle Scholar